Conference on FY2025 (April 1, 2025 to March 31, 2026) Financial Results
Toru Kimura, President and CEO Sumitomo Pharma Co., Ltd.
May 13, 2026
Financial Results for FY2025
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 2
Financial Results for FY2025
Financial Results for FY2025 (Core Basis)Revenue increased primarily due to the growth of ORGOVYX® and GEMTESA® and sales milestone revenue from ORGOVYX®
SG&A expenses and R&D expenses decreased due to business structure improvements, partial transfer of the Asian business, and realignment of the regenerative medicine and cell therapy business
Others (core basis)
FY2024: Gain on transfer of the regenerative medicine and cell therapy business
FY2025: Gain on partial transfer of the Asian business +¥49.0B
Adjustment items:
FY2024: Business structure improvement expenses in Japan and North America
FY2024 Results | FY2025 Results | Change | |||
Value | FX impact | % | |||
Revenue | 398.8 | 453.3 | 54.5 | (5.3) | 13.7 |
Cost of sales | 153.2 | 196.4 | 43.2 | (0.9) | 28.2 |
Gross profit | 245.6 | 256.9 | 11.2 | (4.4) | 4.6 |
SG&A expenses | 167.7 | 159.3 | (8.4) | (1.4) | (5.0) |
R&D expenses | 48.5 | 43.9 | (4.5) | (0.4) | (9.4) |
Others (core basis) | 13.7 | 52.3 | 38.6 | ||
Core operating profit | 43.2 | 105.9 | 62.8 | (2.6) | 145.4 |
Adjustment items (negative number indicates net expense) | (14.3) | 1.4 | 15.8 | ||
Operating profit | 28.8 | 107.3 | 78.5 | 272.6 | |
Finance income/costs | (11.2) | (7.0) | 4.2 | ||
Profit before taxes | 17.6 | 100.3 | 82.7 | 469.8 | |
Income tax expenses | (6.0) | (6.5) | (0.5) | ||
Net profit attributable to owners of the parent | 23.6 | 106.9 | 83.2 | 352.2 | |
Billions of JPY
FY2025
Mar. 2 forecasts
449.0
107.0
108.0
102.0
Average rates:
FY2024 Results : 1US$ = ¥152.62, 1RMB = ¥21.11 FY2025 Results : 1US$ = ¥150.67, 1RMB = ¥20.12 FY2025 forecasts : 1US$ = ¥150.00, 1RMB = ¥20.12
Period end rates:
As of the end of March 2025 : 1US$ = ¥149.53, 1RMB = ¥20.59 As of the end of March 2026 : 1US$ = ¥159.90, 1RMB = ¥20.74
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 3
Financial Results for FY2025
Revenue of Major Products in North AmericaFY2024 Results | FY2025 Results | Change | FY2024 Results | FY2025 Results | Change | |||
Value | FX impact | % | ||||||
North America | Millions of USD | Billions of JPY | ||||||
ORGOVYX® | 544 | 1,029 | 484 | 83.1 | 155.0 | 71.9 | (2.0) | 86.6 |
MYFEMBREE® | 84 | 96 | 12 | 12.8 | 14.4 | 1.6 | (0.2) | 12.6 |
GEMTESA® | 431 | 637 | 206 | 65.8 | 96.0 | 30.2 | (1.2) | 46.0 |
RETHYMIC® | 45 | 42 | (3) | 6.8 | 6.3 | (0.5) | (0.0) | (7.1) |
APTIOM® | 258 | 99 | (159) | 39.4 | 14.9 | (24.5) | (0.2) | (62.1) |
Others | 80 | 56 | (24) | 12.2 | 8.0 | (4.2) | (0.1) | (34.3) |
Export products/ One-time revenue, etc.* | 208 | 287 | 78 | 31.8 | 43.3 | 11.5 | (0.7) | 36.1 |
Total | 1,650 | 2,245 | 595 | 251.8 | 337.9 | 86.1 | (4.5) | 34.2 |
ORGOVYX® and GEMTESA® revenue increased significantly year-on-year
APTIOM® revenue decreased due to loss of exclusivity
Sales milestone revenue from ORGOVYX® has been recognized
* Major items included in Export products/One-time revenue, etc. | |||||
Deferred revenue from | |||||
FY2024 Results | Deferred revenue from the collaboration with Pfizer | $171M | FY2025 Results | the collaboration with Pfizer Sales milestone revenue from ORGOVYX® | $88M $100M |
(sales exceeding $500M) | |||||
Average rates:
FY2024 Results : 1US$ = ¥152.62 FY2025 Results : 1US$ = ¥150.67
© Sumitomo Pharma Co., Ltd. All Rights Reserved. 4
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |